ICML 2023 | Insights into the Phase II Smart Stop study
Jason Westin
• 16 Jun 2023
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the Smart Stop study, which is evaluating the safety and efficacy of rituximab, lenalidomide, acalabrutinib and tafasitamab alone and in combination with chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL; NCT04978584). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
